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a  b  s  t  r  a  c  t
Dusquetide,  a novel  Innate  Defense  Regulator,  modulates  the  innate  immune  system  at  a  key  convergence
point  in intracellular  signaling  pathways  and  has  demonstrated  activity  in  both  reducing  inﬂammation
and  increasing  clearance  of bacterial  infection.  Innate  immunity  has  also  been  implicated  in the  pathogen-
esis  of oral  mucositis  (OM),  a  universal  toxicity  of  chemoradiation  therapy  (CRT).  Testing  the  hypothesis
that  dusquetide  can mitigate  the  development  and  duration  of  OM,  preclinical  studies  have  been com-
pleted  and  correlated  with  interim  results  from  a  Phase  2 clinical  study  in patients  undergoing  CRT  for
head  and  neck  cancer.  Dusquetide  reduced  the  duration  of OM  in  mouse  and  hamster  models  by approx-
imately  50%,  which  was  recapitulated  by the 50%  reduction  of  severe  OM (SOM)  in  the  Phase  2 trial.  A
reduction  in the  clinical  rate of  infection  was  also  observed,  consistent  with  previously  reported  pre-
clinical  studies.  In aggregate,  these  results  not  only  demonstrate  the  safety  and efﬁcacy  of  dusquetide  in
addressing  this  unmet  medical  need,  but  also  provide  proof  of concept  for the  translation  of dusquetide
action  between  animal  models  and  the  human  clinical  setting,  and  further  support  the  contention  thateywords:
nnate
mmune
ral mucositis
ead and neck cancer
innate  immunity  is  an important  driver  for the  initiation  and  continued  impact  of OM.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).ancer supportive care
usquetideAbbreviations: AUC, area under the curve; CRT, chemoradiation therapy; DAMP,
amage-associated molecular patterns; DRC, data review committee; IDR, innate
efense regulator; IV, intravenous; OM,  oral mucositis; PAMP, pathogen-associated
olecular pattern; SOM, severe oral mucositis; UOM, ulcerative oral mucositis.
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ttp://dx.doi.org/10.1016/j.jbiotec.2016.10.010
168-1656/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u1. Introduction
Oral mucositis (OM) is a universal toxicity of chemoradiation
therapy (CRT) used for cancers of the oral cavity, oropharynx and
larynx, whose incidence continues to increase despite aggressive
intervention (Ryerson et al., 2016). Severe OM (SOM) occurs in
almost 75% of these patients and is among the most debilitat-
ing and painful side effects related to treatment (Elting et al.,
2009). SOM is associated with increased opioid use, weight loss,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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eliance on supplemental feeding and hydration, breaks in treat-
ent, unplanned ofﬁce, or emergency room visits and frequent
ospitalizations resulting in an incremental cost of $18,000 per
atient (Nonzee et al., 2008). OM,  including SOM, is a common
eature of many other treatment regimens for cancers other than
ead and neck, albeit generally occurring with lesser frequency and
uration (Peterson et al., 2011; Kudrimoti et al., 2008).
There are no Food and Drug Administration (FDA)-approved
rugs to ameliorate SOM in patients with head and neck squamous
ell carcinoma. The only approved therapy for oral mucositis in any
ontext is palifermin (Nguyen et al., 2015; Lucchese et al., 2016),
 tissue growth factor that is approved for use in patients with
ematologic malignancies receiving myelotoxic therapy requiring
ematopoietic stem cell support. However, palifermin is associ-
ted with a potential risk of stimulating/encouraging solid tumor
roliferation (McDonnell and Lenz, 2007) and is therefore used in
ematologic cancers only. Other approaches, such as photobiomod-
lation, have also been evaluated, including in head and neck cancer
atients (Fekrazad and Chiniforush, 2014); although, concerns have
een raised here as well about the potential negative impact on
umor control (Sonis et al., 2016)
As the biological complexity of OM has become increasingly
lear, preclinical and clinical data have accumulated supporting a
ole for an exaggerated innate immune response as a key initiat-
ng event and a continuing contributor in its pathogenesis (Sonis,
004). The response of the innate defense system to the result-
ng CRT-induced damage-associated molecular patterns (DAMPs)
esults in an inﬂammatory cascade that culminates in apoptosis
f epithelial stem cells, mucosal atrophy and ultimately ulcera-
ion (Sonis, 2004, 2007; Sonis et al., 2007; Logan et al., 2007). The
esulting ulceration continues to send DAMP signals, as well as
otential pathogen-associated molecular pattern (PAMP) signals
ue to infection, further exacerbating the inﬂammatory response.
herefore, the innate immune response is a potential target to
ttenuate both the incidence and duration of CRT-induced OM
Sonis, 2004, 2007).
Dusquetide (SGX942) is a ﬁrst-in-class Innate Defense Regu-
ator (IDR) that modulates the innate immune response to both
AMPs and DAMPs by binding to p62, a key adaptor protein that
unctions downstream to the key sensing receptors (e.g., toll-like
eceptors [TLRs], etc.) that trigger innate immune activation (Yu
t al., 2009). There are no other drug candidates which target
he p62 protein. When the innate immune sentinel cell is acti-
ated, the presence of dusquetide modulates the cellular signaling
rom a pro-inﬂammatory, pro-macrophage response to an anti-
nﬂammatory, heightened pro-macrophage response. This leads to
ecreased inﬂammation with increased bacterial clearance and tis-
ue healing (North et al., 2016; Scott et al., 2007; Yu et al., 2009).
mportantly, both circulating and tissue resident innate immune
ells respond to dusquetide treatment, making it useful even in
he context of immunosuppression (North et al., 2016). Dusque-
ide therefore has the potential to address each of the stages of
he pathogenesis of oral mucositis, decreasing the innate immune
mpliﬁcation of the damage signaling (and subsequent exacerba-
ion of tissue damage), decreasing the incidence and increasing
he clearance of any secondary infections and aiding in the tissue
ealing and resolution of mucositis. As such, dusquetide would be
xpected to decrease the duration of OM.  Importantly, dusquetide
oes not mitigate the direct damage done by CRT to the tumor (or
he surrounding normal tissue).
The safety of single and multiple ascending doses of intravenous
IV) dusquetide was demonstrated in a placebo-controlled study
f 84 healthy human volunteers, in which dusquetide was  found
o be safe and well tolerated (North et al., 2016). In the groups
eceiving multiple doses, most adverse events (AEs) were related
o minor infusion/venipuncture reactions. Other reported AEs werehnology 239 (2016) 115–125
somnolence (4/20 dusquetide patients, 2/10 placebo patients), ala-
nine aminotransferase (ALT) elevation (3/20 dusquetide patients,
1/10 placebo patients), and back pain (3/20 dusquetide patients,
1/10 placebo patients). In vitro exposure to endotoxin of peripheral
blood cells from the same cohort, demonstrated an increase in anti-
inﬂammatory markers and a decrease in inﬂammatory markers
following administration of low doses (0.15–2.0 mg/kg) of dusque-
tide relative to those subjects exposed to placebo (North et al.,
2016). Blood from patients exposed to high doses (3.0–8.0 mg/kg)
of dusquetide, on the other hand, had responses similar to those
receiving placebo (North et al., 2016).
Given the proposed role of innate immunity in mucositis,
dusquetide was tested ﬁrst in preclinical models of mucositis. Sub-
sequently, dusquetide was assessed in a well-characterized clinical
setting in a Phase 2a study speciﬁcally focusing on oral mucositis
in order to evaluate dusquetide’s safety, efﬁcacy and consistency of
the response with preclinical results.
2. Materials and methods
2.1. Animal models
All experimental procedures using animals were carried out
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health and performed in IACUC-approved research facilities
with the approval of the facility’s Animal Care and Use Committee
(approval numbers 09-1215-03, 09-1215-04 and 10-0527-1 from
the Biomodels LLC IACUC).
2.1.1. Mouse model of chemotherapy-induced mucositis
5-ﬂuorouracil (60 mg/kg IP) was  administered to male C3H/HeN
mice on Days −4 and −2. On Day 0, a chemical burn was  applied to
the underside of the mouse tongue, inducing mucositis which gen-
erally peaked on Day 2 (Sonis et al., 1990). Mouse tongues were
scored from 0 to 5 for mucositis daily from Days 1 to 14 by 2
blinded observers. Body weights were also measured daily and col-
itis severity was determined by video endoscopy on Days 4 and 7.
Dusquetide (25 mg/kg IV) was administered after chemotherapy
on Days −1, 2 and 5 in 3 independent experiments and the average
duration as a percent of the placebo (saline) response was averaged
across the 3 experiments. The dusquetide response was statistically
signiﬁcant (p ≤ 0.01) in each experiment.
2.1.2. Hamster model of fractionated radiation-induced OM
Canulated male Golden Syrian hamsters were treated with
7.5 Gy of radiation, directed at the everted left cheek pouch, on Days
0, 1, 2, 3, 6, 7, 8 and 9 (Ara et al., 2008). Mucositis was  evaluated
every second day by 2 blinded observers between Days 7 and 35,
with peak mucositis severity generally occurring around Day 19.
Dusquetide (25 mg/kg IV) was administered either every third day
between Days 0 and 33 (Q3d D0-33; evaluated in 2 experiments),
every 3rd day between Days 6 and 33 (Q3d D6-33; evaluated in
1 experiment), on days of radiation (evaluated in 2 experiments),
or every third day during radiation treatment (i.e., Days 0, 3, 6
and 9; evaluated in 1 experiment). Results are presented as the
percent duration relative to the placebo (saline) response in each
experiment, and are averaged over 2 experiments where possible.
2.1.3. Mouse model of colitis
Dextran sulfate sodium (DSS) was  administered as a 3% DSS
solution in the drinking water of male C57BL/6 mice from Days
0 to 5 of the study (Hamilton et al., 2011). Colitis was  monitored by
video endoscopy on Days 7, 14 and 21. Dusquetide (25 mg/kg IV)
was administered every third day from Days 0 to 18 (Q3d d0-18),
from Days 3 to 18 (Q3d d3-18) or from Days 6 to 18 (Q3d d6-18).
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istopathology of the colon was evaluated on Day 21 (Supplemen-
al Fig. 1). Statistical analysis was undertaken using t-tests and an
sterisk indicates statistically signiﬁcant differences from placebo
saline) control (p < 0.05).
.1.4. Mouse tumor xenograft model
Sixty female nude mice were implanted with estrogen pellets
nd 2–3 days later 5 × 106 MCF-7 cells were implanted subcuta-
eously. Once tumors reached an average size of 100 mm3, the
nimals were randomized into 6 groups of 10 animals and received
ontrol, dusquetide, paclitaxel + vehicle, paclitaxel + dusquetide,
adiation therapy + vehicle or radiation therapy + dusquetide. Dus-
uetide (25 mg/kg) or vehicle (saline) was administered IV on Days
, 4, 7, 10, and 14. Paclitaxel (6 mg/kg IP) or radiation therapy
2 Gy/Day) was  undertaken on Days 1, 3 and 5. Tumors were mea-
ured (L × W × W/2) on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26
nd 29. An unexpected number of deaths occurred in all treatment
roups, unrelated to treatment with study drug, and thus tumor
olumes can only be reliably interpreted up to Study Day 12.
.2. Peptide
Dusquetide (acetate salt, research name: SGX94) was  synthe-
ized by solution phase synthesis (PPL, Inc.). Peptide purity was
nalyzed by high performance liquid chromatography (HPLC) and
as typically greater than 97%. Dusquetide was formulated in aque-
us solution for intravenous (IV) administration (drug product
esearch name: SGX942).
.3. Phase 2a clinical study
The primary objective of this exploratory trial was to assess
he safety and effectiveness of dusquetide compared to placebo
n attenuating the duration and/or incidence of SOM in patients
ndergoing CRT for head and neck cancer. Secondary objectives
ncluded assessing the effectiveness of the drug in reducing ulcera-
ive oral mucositis (UOM) and determining which patient baseline
haracteristics deﬁne subpopulations in which dusquetide had
articular effectiveness. The null hypothesis was  that dusquetide
ould not positively impact the duration and/or severity of OM.
.3.1. Subjects
This study was conducted in the United States with 21 of 27
ites enrolling at least 1 subject, in accordance with the principles
f the Declaration of Helsinki and with the approval of institutional
eview boards at each center. This Phase 2a study was regis-
ered with ClinicalTrials.gov (NCT02013050). Patient enrollment
as completed between December 2013 and August 2015.
Inclusion/exclusion criteria: Eligible patients were at least 18
ears of age with locally advanced (Stages III-IVA/B) squamous cell
arcinoma of the oral cavity or oropharynx, and adequate organ
unction and performance status. All patients were scheduled to
eceive a continuous course of conventional intensity modulated
adiation therapy (IMRT) administered as single daily fractions of
.0 to 2.2 Gy, with a cumulative radiation dose between 55 and
2 Gy at each of at least 2 oral sites concurrent with cisplatin admin-
stered either weekly (30–40 mg/m2 for up to 7 doses) or every
hird week (80–100 mg/m2 for 3 doses). Patients who had received
urgery were eligible if the surgery had been performed within
0 weeks prior to the planned initial dose of study drug. Patients
ith prior head and neck radiotherapy, chemotherapy within 12
onths, scheduled to receive cetuximab, clinically signiﬁcant organystem dysfunction, or who were pregnant, breast-feeding, or par-
icipating in another interventional clinical trial were not eligible.
ll patients signed written informed consent prior to study enroll-
ent.hnology 239 (2016) 115–125 117
2.3.2. Study design
This was  a double blind, placebo-controlled trial. The initial sam-
ple size of 78 patients for this exploratory study was  set based the
assumption that SGX942 treated patients would have a median
duration of SOM (WHO Grade 3 or higher) of about 11 days and
placebo treated subjects would have a median duration of SOM
of about 27 days. Using these assumptions and no adjustment for
multiple testing, a total of 21 placebo patients and 27 total patients
in the SGX942 1.5 mg/kg group, would yield at least 88% power to
detect a statistical difference (27 days vs. 11 days) with alpha = 0.1
using a log-rank test.
Patients received study drug (i.e., dusquetide or placebo given
IV) within 3 days of starting radiation treatment and then twice
a week (every 3rd day ± 1 day) while receiving radiation therapy.
The initial dose escalation phase of the trial assessed the safety
of dusquetide or placebo given for a maximum of 14 doses to
consecutive cohorts of six patients randomized to dusquetide or
placebo with equal numbers of patients (i.e., 3 placebo: 3 SGX942).
Doses of dusquetide used were 1.5, 3.0 and 6.0 mg/kg. After com-
pletion of the treatment course within a ﬁlled cohort, the data were
reviewed by an independent Data Review Committee (DRC) con-
sisting of a statistician, oncologist and preclinical researcher. Once
the DRC determined that there were no safety concerns, the next
cohort receiving the next higher dose of dusquetide was started.
In the second portion of the trial, patients were randomized to
receive 1.5 mg/kg dusquetide, 6.0 mg/kg dusquetide, or placebo
given twice weekly throughout radiation therapy and random-
ized 4:4:1 respectively to yield an approximately equal distribution
across the placebo, 1.5 and 6.0 mg/kg treatment groups over the
course of the entire study. Following a pre-speciﬁed interim anal-
ysis by the DRC after 84 patients had completed their therapy, an
additional 27 patients were enrolled into the trial, and randomized
equally to 1.5 mg/kg dusquetide or placebo at select sites (Supple-
mental Fig. 2).
All patients receiving any study drug were included in the safety
analyses. Because the incidence of OM is highly correlated to the
cumulative radiation dose received, the primary efﬁcacy popula-
tion was prospectively deﬁned as consisting of patients receiving
a minimum cumulative radiation dose of 55 Gy to the oral cavity
or oropharynx. For the efﬁcacy analyses, patients for both parts of
the study that receive the same dose of dusquetide were pooled.
Because only 3 patients were randomized to the 3.0 mg/kg dus-
quetide, no effectiveness conclusions can be drawn at this dose.
2.3.3. Assessment of OM,  AEs, infections, and tumor response
The severity of OM was  determined using WHO  criteria (Sonis
2004; World Health Organization, 1979) and was  assessed by
trained staff twice weekly from baseline to the last study drug
treatment. If UOM persisted (WHO score ≥2) at last study drug
treatment, OM was further assessed weekly thereafter to the 1-
month follow-up visit, at which point all subjects had a follow-up
evaluation. SOM was  deﬁned as a WHO  score of ≥3 and the dura-
tion of SOM deﬁned as the time between the initial assessment of a
WHO score ≥3 to the last time a score of ≥3 was  noted. Any patient
with unresolved SOM had their duration censored at the time of
the last assessment of OM.  Standard clinical chemistry and hema-
tology studies were performed using samples obtained at baseline,
at 2, 4 and 6 weeks, on the last day of study drug treatment, and
1 month after completion of treatment. AEs were recorded at each
visit, including all clinical diagnoses of infection and the investi-
gator’s assessment as to whether the infection was  severe. Repeat
radiologic scans were obtained 1 month following completion of
treatment and were compared to the staging scans using the RECIST
1.1 criteria (Eisenhauer et al., 2009).
Duration of SOM, severity-weighted duration area under the
curve (AUC), and time to onset were compared using a log-rank
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est. The incidence of OM and incidence of infections was com-
ared using Fisher’s exact test. The objective of this exploratory
tudy was to assess trends in biological efﬁcacy and as such the
tatistical signiﬁcance threshold was prospectively set at p < 0.10.
. Results
.1. Preclinical data
The impact of dusquetide on mucositis was assessed in the con-
ext of chemotherapy-induced mucositis, assessing responses in
oth the oral cavity and the lower gastrointestinal (GI) tract, and
n the context of fractionated radiation, directed at the oral cav-
ty alone. In each case, up to a 50% reduction in the duration of
M was observed (Fig. 1a,b,c). Similar reductions in AUC were also
bserved (Supplemental Fig. 3). The impact of dose was  evaluated
n each study by assessing dosing time and/or frequency. In general,
epeated administration of dusquetide was not associated with
n increased beneﬁt (e.g., Fig. 1a), suggesting that more frequent
osing was not beneﬁcial. This ﬁnding is consistent with previous
tudies in bacterial infection models (North et al., 2016).
To further investigate the extent to which dusquetide may  mit-
gate damage in the lower GI tract, a more severe DSS colitis mouse
odel was utilized (Fig. 1d). By Day 14, all 3 dusquetide treat-
ent regimens demonstrated a statistically signiﬁcant reduction
n endoscopic colitis severity score; however, reduction in Day 7
cores were only observed in groups which had received at least 2
oses of dusquetide by Day 7. On Day 21 all 3 dusquetide groups
ppeared to be responding similarly. Histopathology on Day 21
ndicated that some dusquetide treated groups had statistically sig-
iﬁcantly decreased edema and necrosis, whereas other dusquetide
reated groups had similar responses which did not reach statistical
igniﬁcance (Supplemental Fig. 1).
Pharmacodynamically, dusquetide modulates the innate
efense system and thereby alters the consequent toxicity of
adiation or chemotherapy. Given the proposed role of the innate
efense system in radiation treatment of tumors, speciﬁc evalu-
tion of the impact of dusquetide on radiation tumor treatment
as undertaken using a tumor xenograft model with likelihood
o demonstrate an innate immune mediated interference. Thus,
tudies were undertaken in nude mice with a minimally disturbed
nnate immune system, in which dusquetide had previously
emonstrated efﬁcacy (North et al., 2016), using the MCF-7 tumor
ine (i.e., breast cancer cell line). MCF-7 cells express p62, the
arget of dusquetide action (Abcam Product Datasheet, 2016), and
re Beclin+/− and therefore autophagy deﬁcient, making them
ighly sensitive to interference with p62, a central protein in
he autophagic machinery (Aita et al., 1999; Rosenfeldt and Ryan
009).
Treatment of MCF-7 tumor xenografts with dusquetide showed
o increase in tumor growth or worsening of survival and a trend
owards decreased tumor growth and improvement in survival
ith radiation. Treatment with dusquetide did not interfere with
adiation or chemotherapy (i.e., paclitaxel) treatment of MCF-7
umor growth. Indeed, a trend towards an additive suppression of
umor growth was observed (Fig. 2).
.2. Phase 2a clinical study
.2.1. Patients
A  total of 111 patients were enrolled between December 2013
nd August 2015 at 21 sites (Fig. 3). Five patients in each of
he placebo, 1.5 mg/kg dusquetide, and 6.0 mg/kg dusquetide dose
roups did not receive a cumulative dose of at least 55 Gy of radi-hnology 239 (2016) 115–125
ation to the oral cavity or oropharynx and were not evaluable (i.e.,
were not a part of the modiﬁed Intent to Treat population) (Fig. 3).
Of the 96 evaluable patients, the median age was 58.5 years, 81%
were men, 34% had oral cavity and 66% had oropharyngeal tumors,
76% had Stage IVA disease, 53% had tumors that were human papil-
loma virus (HPV) positive based on p16 immunostaining, and 28%
received surgery. The treatment groups were well balanced with
respect to their baseline characteristics (Table 1).
3.2.2. Safety
The rates and types of reported AEs, serious AEs, changes in
vital signs, and laboratory abnormalities were similar across dose
groups. Speciﬁc assessment of treatment-emergent AEs suggested
a potential shift in some hematology endpoints (e.g., white blood
cell counts, anemia) (Table 2). To test if this expected, unavoid-
able side effect of aggressive CRT was being differentially reported
by different sites (ascertainment bias), the lowest white blood cell
count for each patient was  identiﬁed and this nadir value plotted
for each dose group. The resulting plot shows similar distributions
of nadir white blood cell counts in the dose groups (Fig. 4a). This
suggests that the discrepancies between dose groups reported as
having “white blood cell disorder” AEs can be attributed to incon-
sistency between site and/or physician reporting and not an actual
concern.
Another numeric difference is seen in patients with reported
anemia. The nadir measurements for anemia are shown in
Fig. 4b,c,d, also indicating no association with anemia and dusque-
tide (SGX942) dosing.
3.2.3. Efﬁcacy
Patients receiving 1.5 mg/kg of dusquetide had a 50% reduction
in their median duration of SOM compared to the placebo group
(18 versus 9 days for the placebo and dusquetide groups, respec-
tively; Fig. 5a). This ﬁnding was  supported by a 39% reduction in the
median AUC for the WHO  Grade-time calculation (35.5 versus 21.8
score-days for the placebo and dusquetide groups, respectively), a
71% reduction in the rate of SOM through 1-month after completion
of treatment (from 21% in the placebo group to 5% in the dusquetide
group) and a 7% relative reduction in the incidence of SOM when
compared to placebo (from 74% in the placebo group to 69% in the
dusquetide group; Supplemental Table 1). In the 6.0 mg/kg group,
the results were inconsistent across outcomes (Supplemental Table
1).
Several subpopulations of patients were prospectively identi-
ﬁed for further analyses. The duration of SOM of placebo-treated
patients was  greater among individuals treated with cisplatin every
third week (80–100 mg/m2; 30 days) compared to placebo-treated
patients treated with weekly cisplatin (30–40 mg/m2; 10 days). In
those patients receiving cisplatin every third week, there was  a 67%
decrease in the median duration of SOM (i.e., from 30 to 10 days in
the placebo and dusquetide 1.5 mg/kg dose groups, respectively;
Fig. 5b), which was  associated with a 51% reduction in the median
AUC WHO  Grade-time calculation, and an 18% relative reduction in
incidence of severe OM compared to placebo (Supplemental Table
1). Among patients receiving weekly 30–40 mg/m2 cisplatin, the
median duration of SOM was  decreased 50% from 10 days in the
placebo group to 5 days in the 1.5 mg/kg dusquetide group, which
was associated with a 55% reduction in the median AUC WHO
Grade-time calculation.
Improvements in UOM (WHO grade ≥2) seen in the 1.5 mg/kg
dusquetide dose group were similar to those for SOM but the mag-
nitude of the observed trends was  less. The median duration was
decreased by 12% and the median AUC WHO  Grade-time calculation
was decreased by 22%, with correspondingly stronger affects in the
subpopulation receiving every third week cisplatin (median dura-
M.  Kudrimoti et al. / Journal of Biotechnology 239 (2016) 115–125 119
a) b)
c) d)
Fig. 1. Dusquetide reduces oral mucositis and gastrointestinal damage. (a) Fractionated radiation was  administered to Golden Syrian hamsters on Days 0, 1, 2, 3, 6, 7, 8 and
9.  Dusquetide was  administered on the days indicated and 2 h after radiation if applicable. OM was monitored by blinded scoring by 2 independent observers. Data shown
represents 2 independent experiments. (b) and (c) Chemotherapy was  administered to male C3H/HeN mice on Days −4 and −2 and a chemical burn was  used to enhance
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as  scored from 0 to 4 and the mean colitis score for the group was assessed as a pe
 independent experiments. (d) The extent of colitis in a DSS model in male C57BL/
ion decreased by 22% in the dusquetide 1.5 mg/kg group [51 days]
elative to placebo [65 days]) (Supplemental Table 1).
.2.4. Reported infections
Infections were monitored as AEs from the baseline visit until
 month after the last study drug treatment. The rate of clinically
iagnosed infections was reduced in patients in the dusquetide-
reated groups compared to placebo controls (Fig. 5c; Supplemental
able 2).
.2.5. Tumor response
Tumor status was examined 1 month after completion of treat-
ent using the RECIST 1.1 grading system (Eisenhauer et al., 2009).
usquetide did not impair tumor response. In addition, 47% of sub-
ects in the placebo group and 63% in the 1.5 mg/kg dose group were
eported as having a “complete response” (Fig. 5d; Supplemental
able 3) to CRT.
. Discussion
Dusquetide consistently reduced the duration of OM by approxi-
ately 50% in 2 key preclinical index models of mucositis (Fig. 1a,b).
fﬁcacy was independent of the triggering event causing the OM
i.e., radiation, chemotherapy), consistent with the hypothesis that
he pathogenesis of mucositis is tied to the response of the innateolitis (c) were monitored with blinded scoring by 2 independent observers. Colitis
of the response in the vehicle control group (%Colitis). Data shown is averaged over
e was assessed by blinded scoring (single study).
immune system to the damage rather than the underlying cause of
damage directly (Fig. 1c). Similarly, efﬁcacy was also observed in
both the oral cavity and the lower GI tract, again consistent with
the presumption that oral and GI mucositis are driven by similar
mechanisms in different locations (Keefe, 2007). In another model
of chemotherapy-induced colitis, dusquetide was similarly dosed
every third day and again found to mitigate damage, whether initi-
ated at the same time, during or after the DSS (Fig. 1d). In this model,
efﬁcacy was linked to administering at least 2 doses of dusquetide.
Even in the context of continuing damage (e.g., fractionated radia-
tion, DSS-induced colitis), dusquetide treatment was shown to be
effective (Fig. 1a,c).
Previous studies in rodent infection models (North et al., 2016)
have identiﬁed a dose level between 25 and 50 mg/kg (correspond-
ing to a human equivalent dose between 2 and 4 mg/kg) every
second or third day as optimal. Doses higher than 50 mg/kg were
not tested in mouse efﬁcacy studies due to dosing limitations in the
mouse. Similar results were observed in these studies, where dos-
ing every second or third day was  superior to daily dosing (Fig. 1a).
In each case, dusquetide was efﬁcacious when administered after
the damaging stimulus was applied (e.g., after irradiation (Fig. 1a)
or chemotherapy (Fig. 1b,c,d)). This treatment modality was chosen
as a mimic of the most clinically convenient treatment course.
In pharmacodynamic studies in both cynomolgus monkeys and
humans, where dusquetide was administered IV and blood was
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Fig. 2. Dusquetide may  augment tumor suppression with chemotherapy or radiation treatment. Dusquetide (25 mg/kg IV) was administered to female nude mice both alone
and  in combination with radiation and/or chemotherapy treatment on the indicated days. Study outcomes in terms of both survival (top graphs) and tumor volumes (bottom
graph) are shown and indicate both increased survival and decreased tumor volume with dusquetide treatment.
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rFig. 3. CONSORT
rawn and evaluated directly (monkeys) or stimulated with endo-
oxin ex vivo (humans), higher dusquetide doses did not yield
tronger responses (North et al., 2016). In monkeys at dose lev-
ls of 3, 30 and 240 mg/kg, the responses of the anti-inﬂammatory
L-1ra levels were found to be highest at 3 and 30 mg/kg (corre-
ponding to a human equivalent dose of 1–10 mg/kg) (North et al.,
016). Similarly, in a Phase 1 clinical study, anti-inﬂammatory
esponses were highest after administration of dose levels betweennt ﬂow diagram.
0.15 and 2.0 mg/kg, while individuals receiving doses between
3.0 and 8.0 mg/kg were indistinguishable from the placebo group
(North et al., 2016). These data in aggregate clearly suggest that
the adage “more is better” does not hold for this immune regulator.
Hormetic, or non-monotonic, dose response curves are well known
in immune biology, generally arising due to a balance of competing
pathways (Liu 2003; Pearce et al., 2014).
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Table  1
IDR-OM-01 baseline patient characteristics.
Parameter Placebo n = 38 Dusquetide Total n = 96
1.5 mg/kg n = 36 3.0 mg/kg n = 3 6.0 mg/kg n = 19
Age in years
Median 59.5 56.5 54.0 59.0 58.5
Mean  59.1 57.8 48.3 57.9 58.0
Standard Deviation 9.70 8.1 20.11 7.63 9.16
Sex
Males- n (%) 30 (79%) 30 (83%) 1 (33%) 17 (89%) 78 (81%)
Females- n (%) 8 (21%) 6 (17%) 2 (67%) 2 (11%) 18 (19%)
Race:  number (% dose group)
White/Caucasian 35 (92%) 31 (86%) 3 (100%) 18 (95%) 87 (91%)
Black/African-American 1 (3%) 5 (14%) 0 (0%) 1 (5%) 7 (7%)
Asian  1 (3%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Native  Hawaiian 1 (3%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Other  0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Ethnicity: number (% dose group)
Hispanic 1 (3%) 2 (6%) 0 (0%) 3 (16%) 6 (6%)
Non-Hispanic 37 (97%) 33 (92%) 3 (100%) 16 (84%) 89 (93%)
Missing 0 (0%) 1 (3%) (0%) 0 (0%) 1 (1%)
Local  of tumor: number (% dose group)
Oral cavity 12 (32%) 15 (42%) 1 (33%) 5 (26%) 33 (34%)
Oropharynx 26 (68%) 21 (58%) 2 (67%) 14 (74%) 63 (66%)
AJCC  Stage
II 3 (8%) 0 (0%) 0 (0%) 0 (0%) 3 (3%)
III  4 (11%) 7 (19%) 0 (0%) 6 (32%) 17 (18%)
IV  A 30 (79%) 29 (81%) 3 (100%) 11 (58%) 73 (76%)
IV  B 1 (3%) 0 (0%) 0 (0%) 2 (11%) 3 (3%)
Tumor  Classiﬁcation
T1 6 (16%) 8 (22%) 0 (0%) 1 (5%) 15 (16%)
T2  13 (34%) 13 (36%) 2 (67%) 9 (47%) 37 (39%)
T3  9 (24%) 7 (19%) 1 (33%) 3 (16%) 20 (21%)
T4  4 (11%) 3 (8%) 0 (0%) 1 (5%) 8 (8%)
T4a  4 (11%) 5 (14%) 0 (0%) 4 (21%) 13 (14%)
T4b  2 (5%) 0 (0%) 0 (0%) 1 (5%) 3 (3%)
Lymph  Node Classiﬁcation
N0 3 (8%) 2 (6%) 0 (0%) 2 (11%) 7 (7%)
N1  5 (13%) 6 (17%) 0 (0%) 4 (21%) 15 (16%)
N2  29 (76%) 28 (78%) 3 (100%) 12 (63%) 72 (75%)
N3  1 (3%) 0 (0%) 0 (0%) 1 (5%) 2 (2%)
HPV  (p16) Statusa
Positive 20 (53%) 18 (50%) 2 (67%) 11 (58%) 51 (53%)
Negative 18 (47%) 17 (47%) 1 (33%) 8 (42%) 44 (46%)
Surgery
Yes  8 (21%) 11 (31%) 2 (67%) 6 (32%) 27 (28%)
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a HPV status not declared for 1 subject.
Given the potential role of dusquetide in immune biol-
gy, including impacting the microenvironment of the tumor, a
enograft study was conducted with a tumor cell line most likely
o be sensitive to p62 (target protein) modulation. No degradation
f tumor control by chemotherapy or radiotherapy was observed,
nd there was a trend towards increased tumor suppression (Fig. 4).
his ﬁnding is not unexpected, given the role of p62 in the tumor
icroenvironment, such as in the context of multiple myeloma
Hiruma et al., 2009).
Based on these ﬁndings, doses for the Phase 2a clinical study
ere selected to represent the 2 “proﬁles” observed in the Phase 1
tudy – one dose representing the “low dose” in the Phase 1 study
1.5 mg/kg representing the low dose range of 0.15–2.0 mg/kg)
nd one representing the “high dose” (6.0 mg/kg representing the
igh dose range of 3.0–8.0 mg/kg). While both doses were tested,
fﬁcacy was anticipated at the low dose (1.5 mg/kg) due to the anti-
nﬂammatory activity observed in the Phase 1 study and the efﬁcacy
bserved in preclinical studies around this dose level (25–50 mg/kg
n a mouse corresponds to 1.5–4 mg/kg in a human).1 (33%) 13 (68%) 69 (72%)
Upon discussion with FDA, an interim dose was  recommended,
allowing for a more gradual dose escalation. As the 3.0 mg/kg dose
level was  introduced for safety reasons, no efﬁcacy analysis of this
group was planned given the limited number of subjects incor-
porated (3 placebo, 3 dusquetide subjects only were included in
this cohort). Provision was  included in this Phase 2a hypothesis-
generating study for an independent DRC review of patient data
prior to dose escalation (from 1.5 to 3.0 mg/kg, from 3.0 to 6.0 mg/kg
and prior to proceeding with additional enrollment at 6.0 mg/kg),
as well as an interim review whereupon additional subjects could
be recommended to be enrolled.
Consistent with the Phase 1 study, no treatment-emergent
changes in vital signs, laboratory values, AEs or serious AEs were
found to be attributed to dusquetide treatment. In this population,
dusquetide (SGX942) appears to be safe and well tolerated.In the present study, the incidence of SOM in the placebo arm of
74%, the early discontinuation of patient participation in the trial
of 14%, and the frequency of reported AEs are consistent with other
recently published data (Nien et al., 2016; Henke et al., 2011) sug-
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Table 2
Summary of treatment-emergent adverse events in the IDR-OM-01 safety population.
Organ System SGX942 Placebo (N = 41) Totala(N = 109)
Preferred Term 1.5 mg/kg (N = 42) 3.0 mg/kg (N = 3) 6.0 mg/kg (N = 23)
Blood and lymphatic system disorders 23 (55%) 1 (33%) 10 (44%) 14 (34%) 48 (44%)
Anemia 13 (31%) 1 (33%) 6 (26%) 5 (12%) 25 (23%)
White  blood cell disorder 16 (38%) 1 (33%) 6 (26%) 6 (15%) 29 (27%)
Cardiac disorders 5 (12%) 1 (33%) 2 (9%) 2 (5%) 10 (9%)
Ear  and labyrinth disorders 10 (24%) 1 (33%) 5 (22%) 12 (29%) 28 (26%)
Tinnitus 6 (14%) 0 5 (22%) 9 (22%) 20 (18%)
Endocrine disorders 0 0 0 1 (2%) 1 (1%)
Eye  disorders 2 (5%) 0 1 (4%) 0 3 (3%)
Gastrointestinal disorders 40 (95%) 3 (100%) 22 (96%) 39 (95%) 104 (95%)
General  disorders and administration site conditions 32 (76%) 3 (100%) 16 (70%) 31 (76%) 82 (75%)
Immune system disorders 0 0 0 2 (5%) 2 (2%)
Infections and infestations 26 (62%) 1 (33%) 9 (39%) 28 (68%) 64 (59%)
Injury,  poisoning and procedural complications 17 (41%) 1 (33%) 7 (30%) 14 (34%) 39 (36%)
Metabolism and nutrition disorders 37 (88%) 2 (67%) 17 (74%) 28 (68%) 84 (77%)
Musculoskeletal and connective tissue disorders 6 (14%) 1 (33%) 7 (30%) 6 (15%) 20 (18%)
Neoplasms benign, malignant and unspeciﬁed (includes cysts and polyps) 3 (7%) 0 0 0 3 (3%)
Nervous system disorders 31 (74%) 3 (100%) 16 (70%) 22 (54%) 72 (66%)
Dysgeusia 22 (52%) 2 (67%) 13 (57%) 11 (27%) 48 (44%)
Psychiatric disorders 8 (19%) 1 (33%) 10 (44%) 11 (27%) 30 (28%)
Renal  and urinary disorders 16 (38%) 1 (33%) 3 (13%) 8 (20%) 28 (26%)
Respiratory, thoracic and mediastinal disorders 30 (71%) 2 (67%) 14 (61%) 18 (44%) 64 (59%)
Skin  and subcutaneous tissue disorders 22 (52%) 1 (33%) 12 (52%) 16 (39%) 51 (47%)
a Safety population = all patients receiving at least one dose of study drug.
Fig. 4. The nadir of hematological parameters is unchanged across treatment groups. The minimum reported value for each parameter and each patient was determined
between baseline and the initial follow-up visits (1 month post completion of radiation).
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a) b)
c) d)
Fig. 5. Dusquetide efﬁcacy is seen across multiple endpoints in an exploratory Phase 2 trial. All patients receiving CRT including at least 55 Gy radiation (a), as well as the
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nd  a trend towards increased “complete” resolution of tumor at the 1-month follo
he  1-month follow-up visit were excluded from the calculation of incidence.
esting that the placebo group is representative of the head and
eck cancer patient population.
Dusquetide at the 1.5 mg/kg dose was effective in decreasing the
uration of SOM in patients with squamous cell carcinoma of the
ral cavity or oropharynx undergoing concomitant CRT (Fig. 5a,b).
he results in the 6.0 mg/kg dusquetide dose group compared to
he placebo group are inconsistent across the various measures of
OM and across the various subpopulations (Fig. 5a,b; Supplemen-
al Table 1), suggesting that it is not as effective in ameliorating
M as the 1.5 mg/kg dusquetide dose; however, the limited sam-
le size in the 6.0 mg/kg group makes any conclusions uncertain.
ecreased effectiveness at the 6.0 mg/kg dose level would be con-
istent with ﬁndings in the Phase 1 study with dusquetide, where
nti-inﬂammatory activity was more prevalent at the lower dose
evel (North et al., 2016).
The 50% reduction in the duration of SOM in patients treated
ith dusquetide (Fig. 5a,b) is consistent with the preclinical studies
n both chemotherapy and radiation-induced oral and GI mucositis
n which dusquetide reduced the peak intensity and duration of
ucositis by approximately 50% in the duration of SOM (Fig. 1a,b).
Extensive studies have been conducted with dusquetide in var-
ous preclinical models of bacterial infection (North et al., 2016).
ecause dusquetide affects the host response rather than being
irected at the bacteria, this drug has an effect on infections caused
y gram-negative and gram-positive bacteria as well infectionsof SOM. Consistent with preclinical data, a reduced rate of non-fungal infection (c)
 visit (d) were also observed. Patients with missing or not assessed tumor status at
related to multiple resistant organisms. Dusquetide is an effective
agent both prophylactically and therapeutically (North et al., 2016).
Our ﬁnding that the treated groups had fewer bacterial infections
(Fig. 5c, Supplemental Table 2) is very consistent with preclinical
animal models. Similarly, the potential reduction in tumor volume
observed in preclinical studies (Fig. 4) was echoed in the increased
rate of “complete resolution” tumor status at the 1-month follow-
up visit in the Phase 2a study (Fig. 5d, Supplemental Table 3).
The treatment of OM has been fraught with many clinical fail-
ures, beginning with treatments targeted at infected ulcers (e.g.,
antibiotic mouthwashes). Further studies, including the use of
DNA and RNA biomarkers (Sonis et al., 2002), have demonstrated
that OM is an inherently inﬂammatory condition related to the
activation of the innate immune system in response to the dam-
age caused by CRT. Under this hypothesis, treatments modulating
the innate immune response have been suggested as an alterna-
tive approach. IDRs such as dusquetide address all phases of OM,
decreasing the initial inﬂammatory response to damage, mitigat-
ing the inﬂammatory ampliﬁcation phase, providing anti-infective
activity during the ulcerative phase and potentially aiding in tis-
sue healing through the recruitment of macrophages (Scott et al.,
2007; North et al., 2016). This exploratory Phase 2a study has fur-
ther validated the underlying hypothesis regarding innate immune
contribution to OM pathogenesis and has demonstrated that treat-
ment with an IDR has the potential to not only reduce the impact
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f OM,  but also to provide ancillary beneﬁts of reducing infections
nd potentially aiding in the treatment of the underlying tumor.
The highly conserved nature of the innate immune system sug-
ests that animal models should provide realistic models of the
uman clinical condition. Nonetheless, dusquetide has a unique
echanism of action, heretofore untested in the human setting.
hese preclinical and clinical studies have indicated that all of the
iological functions observed in the preclinical setting were trans-
erred to the clinical setting, including reduction in duration of OM
nd reduction in infection. These ﬁndings provide biological proof
f concept for the IDR platform and indicate that other preclinical
DR activity is more likely to translate to the clinical setting.
In conclusion, dusquetide was shown to be effective, reducing
he duration of SOM in head and neck cancer patients, and safe and
ell tolerated in an exploratory Phase 2a study. The results of this
linical study were consistent with preclinical ﬁndings, including
eduction in OM,  reduction in acute inﬂammation and reduction in
he incidence of infection.
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